European Union - English - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

European Union - English - EMA (European Medicines Agency)

ge healthcare as - mangafodipir trisodium - magnetic resonance imaging - contrast media - this medicinal product is for diagnostic use only.contrast medium for diagnostic magnetic resonance imaging (mri) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. as an adjunct to mri to aid in the investigation of focal pancreatic lesions.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - suppository, compressed - excipient ingredients: purified talc; povidone; macrogol 6000; magnesium stearate - treatment of ulcerative procitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - ? hypoxia of any cause. ? as diluent for gaseous and volatile anaesthetic agents.

Ireland - English - HPRA (Health Products Regulatory Authority)

boc gases ireland ltd - oxygen; nitrous oxide - medicinal gas, compressed - 50 %v/v/50 percent volume/volume - other general anesthetics; nitrous oxide

Ireland - English - HPRA (Health Products Regulatory Authority)

boc gases ireland ltd - oxygen - medicinal gas, compressed - 21 percent volume/volume - medical gases; oxygen

Ireland - English - HPRA (Health Products Regulatory Authority)

boc gases ireland ltd - carbon dioxide - medicinal gas, liquefied - 99.5 percent weight/volume - medical gases; carbon dioxide